ARENA PHARMACEUTICALS INC Form 8-K February 17, 2005

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 16, 2005

Arena Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction

000-31161 (Commission File Number) 23-2908305

(I.R.S. Employer

of Incorporation)

Identification No.)

6166 Nancy Ridge Drive, San Diego, California 92121


(Address of Principal Executive Offices) (Zip Code)

(858) 453-7200

(Registrant s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)



23-2908305

Item 2.02. Results of Operations and Financial Condition.

On February 16, 2005, Arena Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2004. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press release issued February 16, 2005, announcing financial results for the fourth quarter and full year ended December 31, 2004.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 16, 2005

Arena Pharmaceuticals, Inc.,
a Delaware corporation

By: /s/ Jack Lief

Jack Lief

President & Chief Executive

Officer

EXHIBIT INDEX

Exhibit No.	<u>Description</u>
99.1	Press release issued February 16, 2005, announcing financial results for the fourth quarter and full year ended December 31, 2004.